

Wolfgang R Sperr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8755097/publications.pdf>

Version: 2024-02-01

210
papers

11,199
citations

30551

56
h-index

38517

99
g-index

212
all docs

212
docs citations

212
times ranked

8239
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	3.3	29
2	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	7.7	77
3	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	2.0	20
4	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	2.0	35
5	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	1.5	19
6	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1866-1874.	1.5	18
7	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 3070.	1.7	0
8	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph ⁺ chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1215-1225.	2.0	14
9	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. <i>Leukemia</i> , 2022, 36, 2108-2120.	3.3	22
10	Hereditary α -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. <i>Blood</i> , 2021, 137, 238-247.	0.6	113
11	Emicizumab for the treatment of acquired hemophilia A. <i>Blood</i> , 2021, 137, 410-419.	0.6	83
12	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	0.7	6
13	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	4.6	26
14	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	1.7	7
15	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2458.	1.8	23
16	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
17	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
18	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	2.0	13
20	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2083-2086.	2.0	16
21	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. <i>American Journal of Hematology</i> , 2021, 96, 719-726.	2.0	1
22	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	2.0	33
23	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	2.0	31
24	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.3	14
25	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?. <i>Journal of Hematopathology</i> , 2021, 14, 325-332.	0.2	0
26	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
27	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	2.3	1
28	Prevalence and Impact of Vitamin D Deficiency in Critically Ill Cancer Patients Admitted to the Intensive Care Unit. <i>Nutrients</i> , 2021, 13, 22.	1.7	5
29	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. <i>American Journal of Cancer Research</i> , 2021, 11, 955-967.	1.4	0
30	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	0.6	6
31	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	1.7	21
32	Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. <i>Seminars in Cancer Biology</i> , 2020, 60, 191-201.	4.3	15
33	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020, 61, 1075-1083.	0.6	11
34	Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1331-1343.	1.6	11
35	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
36	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	1.5	23

#	ARTICLE	IF	CITATIONS
37	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	2.0	8
38	multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 415-422.	1.0	0
39	Comparison of <i>BCR-ABL1</i> quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1214-1222.	1.4	1
40	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	2.7	47
41	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	1.8	11
42	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	0.6	1
43	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
44	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
45	Phenotyping of Disease-Initiating CD34+/CD38 ⁺ Stem Cells in BCR-ABL1 ⁺ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. <i>Blood</i> , 2020, 136, 53-53.	0.6	0
46	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.0	18
47	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
48	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	1.8	44
49	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	0.8	82
50	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2976.	1.8	64
51	Identification of a leukemia-initiating stem cell in human mast cell leukemia. <i>Leukemia</i> , 2019, 33, 2673-2684.	3.3	21
52	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	2.0	150
53	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	1.8	50
54	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14

#	ARTICLE	IF	CITATIONS
55	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2019, 77, 8-13.	0.4	0
56	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	2.0	42
57	Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 583-593.	2.7	32
58	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	3.3	29
59	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4223-4223.	0.6	1
60	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	1.7	30
61	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 115-125.	1.0	0
62	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. <i>Expert Review of Hematology</i> , 2018, 11, 109-116.	1.0	3
63	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	0.8	1
64	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	1.5	49
65	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018, 73, 51-57.	0.4	20
66	Phenotyping and Target Expression Profiling of CD34+/CD38 ^{low} and CD34+/CD38 ⁺ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2018, 20, 632-642.	2.3	32
67	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	1.7	49
68	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
69	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	0.6	18
70	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBF) Tj ETQ 0 0 0 rg BT /Overlo	1.3	17
71	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	0.6	132
72	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. <i>Blood</i> , 2018, 132, 1722-1722.	0.6	5

#	ARTICLE	IF	CITATIONS
73	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. <i>Blood</i> , 2018, 132, 1363-1363.	0.6	2
74	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
75	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.4	58
76	Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. <i>Experimental Hematology</i> , 2017, 51, 17-24.	0.2	31
77	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	0.6	24
78	Prevalence of Comorbidities in Periodontitis Patients Compared to the General Austrian Population. <i>Journal of Periodontology</i> , 2017, 89, 1-13.	1.7	18
79	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥ 60 years. <i>American Journal of Hematology</i> , 2017, 92, E567-E574.	2.0	9
80	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24
81	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	2.2	130
82	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 404-410.	1.0	4
83	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	1.8	19
84	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <i>International Journal of Molecular Sciences</i> , 2017, 18, 415.	1.8	45
85	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
86	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	0.8	13
87	The pan-BCL-2-blocker obatoclox (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. <i>Oncotarget</i> , 2017, 8, 67709-67722.	0.8	13
88	Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review. <i>ESMO Open</i> , 2016, 1, e000018.	2.0	70
89	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	0.6	23
90	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76

#	ARTICLE	IF	CITATIONS
91	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016, 128, 902-910.	0.6	140
92	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	1.7	60
93	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. <i>American Journal of Hematology</i> , 2016, 91, 1239-1245.	2.0	10
94	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
95	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016, 128, 2096-2097.	0.6	46
96	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , 2016, 9, 39.	6.9	36
97	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	3.2	52
98	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	1.5	289
99	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 ^{bright} NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. <i>Oncotarget</i> , 2016, 7, 46466-46481.	0.8	19
100	Evaluation of <i>in vitro</i> effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 65627-65642.	0.8	6
101	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. <i>Haematologica</i> , 2015, 100, 205-213.	1.7	20
102	Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features. <i>Leukemia Research</i> , 2015, 39, 1-5.	0.4	90
103	A novel pump-driven veno-venous gas exchange system during extracorporeal CO ₂ -removal. <i>Intensive Care Medicine</i> , 2015, 41, 1773-1780.	3.9	36
104	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 12-15.	1.0	1
105	Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. <i>European Journal of Haematology</i> , 2015, 95, 75-82.	1.1	10
106	Influenza vaccination perception and coverage among patients with malignant disease. <i>Vaccine</i> , 2015, 33, 1682-1687.	1.7	47
107	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. <i>Blood</i> , 2015, 126, 2515-2515.	0.6	5
108	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084.	0.8	50

#	ARTICLE	IF	CITATIONS
109	Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML. <i>Blood</i> , 2015, 126, 1571-1571.	0.6	0
110	Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. <i>Clinical Cancer Research</i> , 2014, 20, 3589-3602.	3.2	26
111	The <i>KIT</i> <i>D816V</i> allele burden predicts survival in patients with mastocytosis and correlates with the <i>WHO</i> type of the disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 810-813.	2.7	86
112	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.4	59
113	The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 1-16.	2.0	24
114	Clofarabine/cyclophosphamide for debulking before stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2014, 44, 775-783.	1.7	3
115	The serum tryptase test: an emerging robust biomarker in clinical hematology. <i>Expert Review of Hematology</i> , 2014, 7, 683-690.	1.0	65
116	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the ACGM-Study Group. <i>Annals of Hematology</i> , 2014, 93, 1825-1838.	0.8	84
117	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	0.8	146
118	Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. <i>Thrombosis Research</i> , 2014, 133, 303-305.	0.8	28
119	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.2	12
120	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 3951-3962.	0.6	189
121	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	0.6	5
122	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	0.6	2
123	Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma. <i>Blood</i> , 2014, 124, 2633-2633.	0.6	1
124	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	0.6	3
125	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. <i>Blood</i> , 2014, 124, 3683-3683.	0.6	1
126	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 817-817.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	0.6	2
128	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	0.6	26
129	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. <i>Blood</i> , 2014, 124, 4526-4526.	0.6	0
130	Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS. <i>Blood</i> , 2014, 124, 1570-1570.	0.6	14
131	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1422-1422.	0.6	0
132	Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. <i>American Journal of Blood Research</i> , 2014, 4, 93-100.	0.6	11
133	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 114-118.	0.3	0
134	Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. <i>Immunobiology</i> , 2013, 218, 1155-1165.	0.8	5
135	Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. <i>American Journal of Hematology</i> , 2013, 88, 533-534.	2.0	7
136	Proposed score for survival of patients with myelodysplastic syndromes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1120-1128.	1.7	12
137	Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants. <i>Blood</i> , 2013, 122, 1654-1654.	0.6	1
138	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. <i>Blood</i> , 2013, 122, 257-257.	0.6	41
139	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). <i>American Journal of Blood Research</i> , 2013, 3, 174-80.	0.6	16
140	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	0.9	513
141	Diagnosis, progression patterns and prognostication in mastocytosis. <i>Expert Review of Hematology</i> , 2012, 5, 261-274.	1.0	37
142	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.0	33
143	Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation. <i>Vaccine</i> , 2012, 30, 6864-6870.	1.7	7
144	Clofarabine/Cyclophosphamide (ClfCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4504-4504.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 354-358.	1.0	2
146	Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. <i>Blood</i> , 2011, 118, 2753-2753.	0.6	6
147	Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥ 60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy. <i>Blood</i> , 2011, 118, 2504-2504.	0.6	0
148	How I treat patients with advanced systemic mastocytosis. <i>Blood</i> , 2010, 116, 5812-5817.	0.6	106
149	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. <i>Experimental Hematology</i> , 2010, 38, 744-755.	0.2	46
150	Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. <i>Annals of Oncology</i> , 2010, 21, 114-119.	0.6	103
151	High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming <i>KIT</i> mutation D816V. <i>Molecular Oncology</i> , 2010, 4, 335-346.	2.1	44
152	Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 369-378.	0.7	53
153	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-96.	0.8	28
154	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-496.	0.8	52
155	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. <i>Blood</i> , 2010, 116, 3382-3382.	0.6	0
156	Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. <i>European Journal of Clinical Investigation</i> , 2009, 39, 914-923.	1.7	84
157	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. <i>Blood</i> , 2009, 114, 4263-4263.	0.6	0
158	Expression and prognostic significance of different mRNA 5' end variants of the oncogene <i>EV11</i> in 266 patients with de novo AML: <i>EV11</i> and <i>MDS1/EV11</i> overexpression both predict short remission duration. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 288-298.	1.5	55
159	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. <i>Journal of Immunology</i> , 2008, 180, 5466-5476.	0.4	75
160	Impact of Age and Comorbidity in Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 927-934.	2.3	37
161	Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 158-164.	0.9	111
162	Rituximab for the treatment of acquired antibodies to factor VIII. <i>Haematologica</i> , 2007, 92, 66-71.	1.7	98

#	ARTICLE	IF	CITATIONS
163	Biology and clinical features of myeloid neoplasms with inv(3) (q21q26) or t(3;3) (q21q26). <i>Leukemia and Lymphoma</i> , 2007, 48, 2096-2097.	0.6	5
164	Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 192-199.	1.5	30
165	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.4	478
166	Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care.. <i>Blood</i> , 2007, 110, 2860-2860.	0.6	0
167	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. <i>Blood</i> , 2007, 110, 4556-4556.	0.6	0
168	Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFR α , classification by WHO criteria, and response to therapy with imatinib. <i>Leukemia Research</i> , 2006, 30, 1201-1205.	0.4	37
169	Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. <i>Journal of Immunology</i> , 2006, 176, 1759-1768.	0.4	5
170	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes.. <i>Blood</i> , 2006, 108, 4828-4828.	0.6	0
171	High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. <i>Leukemia Research</i> , 2005, 29, 609-615.	0.4	18
172	Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2005, 11, 6787-6792.	3.2	54
173	Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. <i>Clinical Cancer Research</i> , 2005, 11, 6536-6543.	3.2	17
174	Indolent Systemic Mastocytosis with Elevated Serum Tryptase, Absence of Skin Lesions, and Recurrent Severe Anaphylactoid Episodes. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 273-280.	0.9	77
175	CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. <i>Leukemia and Lymphoma</i> , 2005, 46, 1115-1120.	0.6	27
176	Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48.	0.6	180
177	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.. <i>Blood</i> , 2005, 106, 3518-3518.	0.6	2
178	Phenotyping of Neoplastic (CD34+/CD38 α ~/CD123+) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets.. <i>Blood</i> , 2005, 106, 1381-1381.	0.6	1
179	A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 3965-3971.	3.2	25
180	Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. <i>Leukemia Research</i> , 2004, 28, 249-257.	0.4	138

#	ARTICLE	IF	CITATIONS
181	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non- mast cell hematopoietic neoplasms. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 3-11.	1.5	157
182	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. <i>American Journal of Clinical Pathology</i> , 2004, 121, 473-481.	0.4	30
183	Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.. <i>Blood</i> , 2004, 104, 4741-4741.	0.6	0
184	The Influence of Age and Gender on the Prognostic Impact of Karyotypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.. <i>Blood</i> , 2004, 104, 1448-1448.	0.6	0
185	Treatment concepts for elderly patients with acute myeloid leukemia. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 505-514.	1.0	5
186	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641.	0.4	217
187	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717.	1.2	187
188	Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 137-139.	0.9	61
189	Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 140-142.	0.9	70
190	Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. <i>International Archives of Allergy and Immunology</i> , 2002, 128, 136-141.	0.9	184
191	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. <i>Leukemia and Lymphoma</i> , 2002, 43, 575-582.	0.6	24
192	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 102-109.	1.5	156
193	Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 2257-2261.	0.6	42
194	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. <i>Leukemia Research</i> , 2002, 26, 601-606.	0.4	32
195	Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). <i>The Hematology Journal</i> , 2002, 3, 283-289.	2.0	69
196	Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-xL. <i>Human Pathology</i> , 2001, 32, 545-552.	1.1	109
197	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	0.6	130
198	Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. <i>British Journal of Haematology</i> , 2001, 113, 357-364.	1.2	135

#	ARTICLE	IF	CITATIONS
199	A case of "smouldering" mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. <i>Leukemia Research</i> , 2001, 25, 627-634.	0.4	43
200	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.4	1,020
201	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. <i>Leukemia Research</i> , 2001, 25, 595-602.	0.4	67
202	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leukemia Research</i> , 2001, 25, 529-536.	0.4	206
203	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.4	124
204	Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. <i>FASEB Journal</i> , 2001, 15, 2042-2044.	0.2	117
205	Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis. <i>Leukemia and Lymphoma</i> , 2000, 37, 473-486.	0.6	101
206	Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF and timothy grass pollen allergen, Phl p 7. <i>FASEB Journal</i> , 1999, 13, 843-856.	0.2	105
207	B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. <i>FASEB Journal</i> , 1999, 13, 1277-1290.	0.2	73
208	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. <i>European Journal of Immunology</i> , 1999, 29, 2026-2036.	1.6	138
209	Mast Cell-Lineage Versus Basophil Lineage Involvement in Myeloproliferative and Myelodysplastic Syndromes: Diagnostic Role of Cell-Immunophenotyping. <i>Leukemia and Lymphoma</i> , 1996, 22, 187-204.	0.6	41
210	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. , 0, .		1